Top-News
Biotechnologie Israel

Prothena Corporation News

Aktie
WKN:  A1KAVV ISIN:  IE00B91XRN20 US-Symbol:  PRTA
20,00 €
+0,00 €
0,00%
08:05:59 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
45,05 Mio.
Marktkapitalisierung *
899,34 Mio. €
Streubesitz
53,90%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 29.10.2021

Unternehmensmeldungen

27.10.22 - GlobeNewswire
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
01.09.22 - GlobeNewswire
Prothena to Participate in Upcoming Healthcare Conferences
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
01.09.22 - GlobeNewswire
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
08.08.22 - GlobeNewswire
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-​end cash and restricted cash ...
02.08.22 - GlobeNewswire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
01.08.22 - GlobeNewswire
Prothena to Report Second Quarter 2022 Financial Results on August 8th
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
01.07.22 - GlobeNewswire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
02.06.22 - GlobeNewswire
Prothena to Participate in Jefferies Healthcare Conference
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
05.05.22 - GlobeNewswire
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-​end cash and restricted cash position was $544.3 million Advanced PRX012, a ...
28.04.22 - GlobeNewswire
Prothena to Report First Quarter 2022 Financial Results on May 5th
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
26.04.22 - GlobeNewswire
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
PRX012 is a potential best-​in-class, subcutaneous anti-​amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, ...
28.03.22 - GlobeNewswire
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- ...
21.03.22 - GlobeNewswire
Prothena to Participate in Stifel 2022 Virtual CNS Days
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
16.03.22 - GlobeNewswire
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to ...
17.02.22 - GlobeNewswire
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full ...
10.02.22 - GlobeNewswire
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
29.11.21 - GlobeNewswire
Prothena to Participate in JMP Securities Hematology and Oncology Summit
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
04.11.21 - GlobeNewswire
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-​end cash and restricted ...
28.10.21 - GlobeNewswire
Prothena to Report Third Quarter 2021 Financial Results on November 4th
DUBLIN, Ireland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical company with a robust pipeline of novel investigational ...
01.10.21 - GlobeNewswire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical company with a robust pipeline of novel investigational ...

Newssuche

Videos

newspaper
12.09.24 +2,89%
Technical Trading: Gold Long bis Juli ´25
Gold Long Typ: Turbo Open End WKN: JT8CZ9 Hebel: 24 Laufzeit: OpenEnd Einstieg: Market ... Mehr »